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It has been reported that the population of regulatory T cells (T regs) is increased in tumour-infiltrating lymphocytes in cancer-bearing
hosts. Recently, forkhead/winged helix transcription factor p3, Foxp3, is thought to be the most reliable marker of T regs. In the
present study, we investigated the prevalence and localisation pattern of Foxp3
þ cells in gastric cancer (n¼80) by
immunohistochemistry, in relation to the clinical outcome of gastric cancer patients. Immunohistochemical staining was performed
with anti-Foxp3 mAb, and Foxp3
þ cells were semiquantified. We divided all cases into two groups: Foxp3
þ-high (n¼40) and
Foxp3
þ-low (n¼40) groups, by the median size of the population of Foxp3
þ cells. Furthermore, in terms of the localisation pattern
of accumulating Foxp3
þ cells in tumours, we classified all cases into three groups: a peri-tumour group (n¼30), a diffuse group
(n¼40), and a follicular group (n¼10). As a result, although the populations of Foxp3
þ cells in stage IV were significantly larger than
those in stage I (Po0.05), there was no significant difference in survival between the patients with high and low population levels of
Foxp3
þ cells. However, survival in patients with a diffuse pattern of Foxp3
þ cells was significantly poorer than in those with a peri-
tumoral pattern. In conclusion, the localisation pattern, but not the population size, of Foxp3
þ cells was significantly related to patient
survival.
British Journal of Cancer (2008) 98, 148–153. doi:10.1038/sj.bjc.6604149 www.bjcancer.com
Published online 18 December 2007
& 2008 Cancer Research UK
Keywords: Foxp3; regulatory T cells; gastric cancer; prognosis
                                             
Regulatory T cells (T regs) are one of the T-cell subsets, which play
important roles in immunological self-tolerance (Sakaguchi et al,
1995; Jonuleit et al, 2001; Ng et al, 2001; Beyer and Schultze, 2006).
They have a functionally immunosuppressive property that
inhibits effector cells from acting against self in autoimmune
diseases or a tumour (Sakaguchi et al, 1995; Jonuleit et al, 2001; Ng
et al, 2001; Beyer and Schultze, 2006). They constitutively express
CD25 (IL-2 receptor a-chain), CD45RO, glucocorticoid-induced
tumour-necrosis factor receptor-related protein, and cytotoxic
T-lymphocyte-associated antigen-4 (Sakaguchi et al, 1995; Dieckmann
et al, 2001; Beyer and Schultze, 2006). Recently, it has been
reported that Foxp3, forkhead/winged helix transcription factor, is
a reliable marker of T regs (Hori and Sakaguchi, 2004; Yagi et al,
2004). Therefore, it is possible to define T regs more strictly as
CD4
þCD25
þFoxp3
þ cells.
In mice, it is known that autoimmune diseases, such as
ulcerative colitis or Crohn’s disease, occur due to the depletion
of T regs (Hori and Sakaguchi, 2004; Sakaguchi et al, 2006). Also in
humans, immune dysregulation polyendocrinopathy enteropathy
X-linked syndrome is an autoimmune disease due to a deficiency
of T regs (Kelsen et al, 2005; Dejaco et al, 2006; Sakaguchi et al,
2006; Takahashi et al, 2006). These observations indicated that T
regs play important roles in immunological homeostasis. Although
the mechanisms of suppression by T regs are still unclear, it has
been reported that T regs can inhibit the function of effector T cells
directly through cell-to-cell contact or indirectly via the secretion
of immune-suppressive cytokines, and also suppress the Ag-
presenting function of dendritic or NK cells (Dieckmann et al,
2002; Misra et al, 2004; Earle et al, 2005; Longhi et al, 2006; Smyth
et al, 2006).
Recently, many studies in murine models have shown that the
depletion of T regs can amplify antitumour immunity (Viehl et al,
2006; Rudge et al, 2007). Moreover, in humans, many studies have
revealed that the population of T regs in tumour-infiltrating
lymphocytes (TILs) is significantly larger than in normal tissues in
several malignancies (Woo et al, 2001; Liyanage et al, 2002;
Ormandy et al, 2005; Badoual et al, 2006; Petersen et al, 2006). We
have reported that the frequency of T regs among TILs, tumour-
draining regional lymph nodes, and peripheral blood lymphocytes
is higher in gastric and oesophageal cancer patients than that
in their normal counterparts (Ichihara et al, 2003). Importantly,
after patients received curative resections of gastric cancers, the
increased proportion of T regs was significantly reduced, and the
levels were almost equal to those in normal healthy donors (Kono
et al, 2006). These results strongly suggest that tumour-related
factors induce and expand T regs. There is, however, still limited
information describing the mechanisms behind T reg accumulation
within cancer microenvironments and their expansion locoregion-
ally. Thus, it is important to evaluate the localisation of infiltrating
T regs in relation to the clinical outcome.
In the current study, we investigated the population and
localisation pattern of Foxp3
þ T regs in gastric cancer by
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simmunohistochemistry, and evaluated the relationship between
the findings and clinical outcome.
MATERIALS AND METHODS
Patients and samples
Eighty patients with gastric cancer, who were operated on in the
University of Yamanashi Hospital from 1997 to 1998, were enrolled
in the present study. The median follow-up time of the patients
was 87.7 months. The characteristics of the study subjects are
summarised in Table 1. None of the patients received radio-
therapy, chemotherapy, or other medical interventions before
the study. This study was approved by the Ethical Committee of
the University of Yamanashi, and written informed consent was
obtained from all individuals.
Immunohistochemical analysis
Foxp3 staining was conducted using the avidin–biotin–peroxidase
complex method with paraffin-embedded, 4-mm-thick sections of
gastric cancer. Briefly, each paraffin section was dewaxed, followed
by antigen retrieval with Epitope Retrieval Solution (10mmol
citrate buffer (pH 6.0), Dakocytomation, Glostrup, Denmark) in a
preheated water bath (981C, 40min), and endogenous peroxidase
was blocked by ChemMate Peroxidase Blocking Solution (Dako).
Then, biotinylated anti-human Foxp3 antibody (diluted by PBS,
1:20; eBioscience, San Diego, CA, USA) was applied for 40min
at room temperature. Thereafter, the sections were incubated with
streptavidin-conjugated horseradish peroxidase (Dako) for 10min,
followed by development with 3,30-diaminobenzidine (Dako) for
5min and counter-staining with haematoxylin. Negative control
staining was performed with isotype control, mouse IgG2a (Dako),
instead of the primary antibody.
Quantitative evaluation of Foxp3
þ cells was analysed in five
randomly selected areas at a magnification of  400 by two
observers (YM and KK) in a blinded manner. Then, all cases with
gastric cancer were divided into two groups: Foxp3
þ-high and
Foxp3
þ-low groups, classified by the median value of the total
population of Foxp3
þ cells (median¼34.5, range¼2–525).
Furthermore, localisation patterns of infiltrating Foxp3
þ cells in
the tumour were divided into three groups: a peri-tumour group, a
diffuse group, and a follicular group. The peri-tumour group was
defined as the population of Foxp3
þ cells in the peri-tumoral
region that had increased more than five-fold compared to that in
the central region of the tumour at a magnification of  400, while
the diffuse group was defined as the difference in the Foxp3
þ cells
between the peri-tumoral region and central region of the tumour
that was less than five-fold. Moreover, the follicular group was
defined as the population of Foxp3
þ cells that mainly occupied the
lymphoid follicles of the submucosal layer compared to any other
region of the tumour.
Statistical analysis
Actuarial overall survival rates were analysed by the Kaplan–Meier
method, and survival was measured in days from the operation to
death or the last review. Differences between survival curves were
analysed by the log-rank test. Deviation in immunohistochemical
patterns was evaluated by the w
2 test.
To assess the correlation between survival time and multiple
clinicopathologic variables, univariate and multivariate analyses
were conducted using Cox’s proportional hazards model. Differences
were considered significant at Po0.05. All statistical analyses
were performed with StatView-J 5.0 software (Abacus Concepts,
Berkeley, CA, USA).
RESULTS
Immunohistochemical analysis of Foxp3
þ cells in gastric
cancer
Foxp3
þ cells were specifically identified and semiquantified by
immunohistochemistry (Figure 1A–C). Then, localisation patterns
of infiltrating Foxp3
þ cells were divided into three groups: a
peri-tumour group (Figure 1A, n¼30), diffuse group (Figure 1B,
n¼40), and follicular group (Figure 1C, n¼10), in terms of where
Foxp3
þ cells dominantly occupied the lesion by immunohisto-
chemistry as described in Materials and Methods. There was a very
small population of Foxp3
þ cells in normal gastric mucosa in the
same specimens (Table 2). The population of Foxp3
þ cells in stage
IV was significantly larger than those in stage I (Table 2, Po0.05).
There were no significant differences in the prevalence of
Foxp3
þ cells among T factors, N factors, or between histological
classifications (Table 2).
Interestingly, tumours with a diffuse distribution pattern of
Foxp3
þ cells were more frequent in stages IIþIIIþIV, while
tumours with a peri-tumoral distribution pattern of Foxp3
þ cells
were more frequent in stage I (Po0.05 by the w
2 test, Table 2).
There were no significant differences in the localisation pattern of
Foxp3
þ cells among T factors or between histological classifications,
although there was significant difference in the localisation pattern
of Foxp3
þ cells among N factors (Table 2).
The frequency and distribution pattern of Foxp3
þ cells
relating to survival in gastric cancer
While the grade of the T factor (Figure 2A), N factor (Figure 2B),
and stage classification (Figure 2C) was significantly correlated
with the survival of patients, there was no significant difference
in survival between patients with large and small populations of
Foxp3
þ cells (Figure 2D). However, the survival rate in patients
Table 1 Patient and tumour characteristics (n¼80)
Age (years, mean±s.d.) 61±13
Gender
Male:female 56:24
Tumour size (mm)
Mean (±s.d.) 54.1±42.3
Tumour
a
pT1 31
pT2 28
pT3 15
pT4 6
Lymph node metastasis
a
pN0 41
pN1 21
pN2 9
pN3 9
Histological classification
Intestinal type 41
Diffuse type 39
Stage
a
IA 3 0
IB 1 2
II 12
III A 11
III B 4
IV 11
aTumour, lymph node metastasis, and stage according to the Japanese Classification
of Gastric Carcinoma (Japanese Gastric Cancer Association, 1998).
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swith a diffuse pattern of Foxp3
þ cells was significantly poorer than
in those with a peri-tumoral pattern (Figure 2E). These results
indicated that the localisation pattern, but not the population size,
of Foxp3
þ cells was significantly related to patient survival.
To further assess whether the localisation pattern of Foxp3
þ
cells represented a prognostic parameter, we used Cox’s propor-
tional hazards model. The covariate parameters included several
clinicopathologic factors, as shown in Table 3. On univariate
analysis, a diffuse group in terms of the localisation of Foxp3
þ
cells showed a significantly higher hazard ratio for a poor
prognosis (vs the peri-tumoral group, hazard ratio¼4.65
(1.35–15.96), Po0.02), although multivariate analysis revealed
that the localisation pattern of Foxp3
þ cells was not an
independent prognostic factor (P¼0.39, Table 3).
DISCUSSION
In general, T regs have functionally suppressive actions on other
effector T cells (Sakaguchi et al, 1995; Dieckmann et al, 2001;
Cancer
×4
×40
Cancer
×40 ×40
×40
×40
×4
×4
Cancer
X40 ×40
Figure 1 Localisation pattern of accumulating Foxp3
þ cells in gastric cancer by immunohistochemistry. Localisation patterns of infiltrating Foxp3
þ cells in
the tumour were divided into three groups: a peri-tumour group (A, n¼30), a diffuse group (B, n¼40), and a follicular group (C, n¼10). Representative
staining is demonstrated. The peri-tumour group was defined as the population of Foxp3
þ cells in the peri-tumoral region that had increased more than
five-fold compared to that in the central region of the tumour at a magnification of  400, while the diffuse group was defined as the difference in the
Foxp3
þ cells between the peri-tumoral region and central region of the tumour that was less than five-fold. The follicular group was defined as the
population of Foxp3
þ cells that mainly occupied lymphoid follicles of the submucosal layer compared to any other region of the tumour (original
magnification:  4,  40).
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sJonuleit et al, 2001; Ng et al, 2001; Earle et al, 2005; Beyer and
Schultze, 2006). They have been characterised as a CD4
þCD25
high
population among CD4
þ T cells (Sakaguchi et al, 1995;
Dieckmann et al, 2001; Jonuleit et al, 2001; Ng et al, 2001; Earle
et al, 2005; Beyer and Schultze, 2006). However, it was difficult to
discriminate T regs from conventional effector T cells that express
CD25 intermediately, because effector T cells continuously express
CD25 on their cell surface (Zheng et al, 2004; Fontenot et al, 2005;
Allan et al, 2007; Pillai et al, 2007). Recently, it has been reported
that Foxp3, forkhead/winged helix transcription factor, is the most
reliable marker of T regs (Hori and Sakaguchi, 2004; Yagi et al,
2004; Fontenot et al, 2005). Therefore, it is possible to define
Tr e g sm o r es t r i c t l ya sC D 4
þCD25
þFoxp3
þ cells. Moreover, Foxp3
expression is crucial regarding whether the cells have a virtually
suppressive function. Thus, Foxp3
þ cells were analysed by
immunohistochemistry in order to evaluate T regs in gastric cancer.
Previous studies in human malignancies reported that the
prevalence of T regs defined as a CD4
þCD25
þ population was
significantly increased in TILs compared to the normal counter-
parts (Woo et al, 2001; Liyanage et al, 2002; Ormandy et al, 2005;
Badoual et al, 2006; Petersen et al, 2006). Furthermore, the high
prevalence of CD4
þCD25
þ T regs is closely associated with a poor
prognosis in ovarian (Curiel et al, 2004) or pancreatic (Liyanage
et al, 2002) cancer. Recently, intratumoral Foxp3
þ T regs in
ovarian (Wolf et al, 2005) or pancreatic (Hiraoka et al, 2006)
cancer were correlated with a poor prognosis (Wolf et al, 2005;
Hiraoka et al, 2006). In particular, multivariate analysis in
pancreatic cancer (Hiraoka et al, 2006) showed that the prevalence
of Foxp3
þ T regs was an independent prognostic factor. On the
contrary, it has been reported that the clinical outcome was not
dependent on the prevalence of Foxp3
þ T regs in TILs in renal cell
carcinoma (Siddiqui et al, 2007). Thus, in human malignancies,
it remains controversial as to whether infiltrating T regs, in
particular Foxp3
þ T regs, are related to the clinical outcome.
In the current study, we analysed the prevalence of Foxp3
þ cells
in gastric cancer by immunohistochemistry. The prevalence of
Foxp3
þ cells was significantly increased in the tumour lesion
compared to normal gastric tissue. Moreover, the population of
Foxp3
þ cells in stage IV was significantly larger than those in
stage I. However, the prevalence of Foxp3
þ cells is not
significantly associated with the overall survival of patients with
gastric cancer, in contrast with previous reports on ovarian
carcinoma (Wolf et al, 2005) and pancreatic cancer (Hiraoka et al,
2006). The present study is, to our knowledge, the first report
describing the prevalence of Foxp3
þ T regs related to the
prognosis in gastric cancer.
With regards to gastric mucosa, there are several reports
describing the presence of Helicobacter pylori infection-associated
Foxp3
þ T regs (Lundgren et al, 2005; Enarsson et al, 2006). Since,
in the present cohort with gastric cancer, there was no information
on H. pylori infection, it is impossible to evaluate the influence of
this infection. Thus, the presence of H. pylori infection may lead
to complications in the evaluation of Foxp3
þ T regs in tumoral
immunity of gastric cancer.
Of note, we found that the patients with a predominant
localisation of Foxp3
þ cells in the peri-tumoral region had a
better prognosis than those showing a diffuse localisation of
Foxp3
þ cells. Since the precise mechanisms inducing and
expanding T regs remain unclear, the biological difference between
the peri-tumoral and diffuse localisation of Foxp3
þ cells is under
investigation. It is possible to presume that a tumour-related factor
may induce an accumulation of Foxp3
þ T regs in the peri-tumoral
region at the early stage of gastric cancer, since stage I patients
with a peri-tumoral localisation pattern were significantly more
frequent. For example, the cancer–stromal reaction including the
migration factors for Foxp3
þ T regs may differ within tumours,
leading to the difference in the localisation pattern of Foxp3
þ T
regs. That is, the migration factors for Foxp3
þ T regs were mainly
produced in the peri-tumoral region as a result of the tumour–
stromal reaction at the early stage of gastric cancer.
In conclusion, the prevalence of Foxp3
þ cells is not significantly
associated with the overall survival of patients with gastric cancer.
However, the patients with a predominant localisation of Foxp3
þ
cells in the peri-tumoral region had a better prognosis than those
showing the diffuse localisation of Foxp3
þ cells. A better
understanding of the underlying mechanism of T reg regulation
or a strategy for controlling T regs may lead to a novel therapeutic
strategy for gastric cancer.
Table 2 Prevalence and localisation pattern of Foxp3
+ cells in the tumour in relation to clinicopathologic status
Patient number relating to localisation pattern of Foxp3
+ cells
No. of Foxp3
+ cells (mean±s.d.) Diffuse (n¼40) Peri-tumour (n¼30) Follicular (n¼10)
Normal gastric mucosa 2.3±1.8
Stage
a
I( n¼42) 47.2±44.0 16** 20** 6
II (n¼12) 54.9±41.5 5 6 1
III (n¼15) 45.3±48.3 11 3 1
IV (n¼11) 107.4±169.7 8 1 2
II+III+IV (n¼38) 66.3±99.5 24** 10** 4
Tumour factor
a
T1 (n¼31) 42.0±35.0 NS 14 11 6
T2 (n¼28) 61.4±51.9 10 16 2
T3 (n¼15) 34.9±45.8 12 3 0
T4 (n¼6) 160.0±217.1 4 0 2
Lymph node metastasis (N factor)
a
Negative (n¼41) 48.0±44.3 NS 16** 19** 6
Positive (n¼39) 65.1±98.5 24** 11** 4
Histological classification
Intestinal (n¼41) 54.8±87.4 NS 16 19 6
Diffuse (n¼39) 57.9±62.2 24 11 4
NS¼not significant.
aStage and tumour factor according to the Japanese Classification of Gastric Carcinoma (Japanese Gastric Cancer Association, 1998). **Po0.05 by the
w
2 test, ***Po0.05 by the non-paired Student’s t-test.
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Figure 2 The localisation pattern, but not the population size, of Foxp3
þ cells was significantly related to patient survival. The median survival time in early
disease was significantly longer than that in advanced disease in terms of the pathologic tumour status (A), pathologic node status (B), and stage (C)( n¼80,
Po0.05, by the log-rank test). (D) Foxp3
þ-high and Foxp3
þ-low groups were classified by the median value of the population of Foxp3
þ cells (median
value¼34.5, range¼2–525). NS: not significant. (E) Localisation patterns of infiltrating Foxp3
þ cells in the tumour were divided into three groups: a peri-
tumour group (n¼30), a diffuse group (n¼40), and a follicular group (n¼10).
Table 3 Univariate and multivariate analysis of the patients
Univariate analysis Multivariate analysis
Overall survival Overall survival
Variables Categories HR (95% CI) P HR (95% CI) P
Age (years) o60 (vs X60) 1.64 (0.71–3.79) 0.25
Gender Male (vs female) 0.42 (0.18–0.98) 0.45
Tumour size (mm) X40 (vs o40) 7.94 (1.84–34.48) 0.0055 0.94 (0.063–14.08) 0.96
Tumour
a pT2+pT3+pT4 (vs pT1) 3.64 (1.23–10.75) o0.0001 0.67 (0.16–2.81) 0.59
Lymph node metastasis
a pN1+pN2+pN3 (vs pN0) 14.29 (3.32–62.50) 0.0003 1.44 (0.13–15.87) 0.76
Stage
a Stages III+IV (vs stages I+II) 8.47 (3.30–21.74) o0.0001 0.67 (0.15–3.08) 0.61
Population of Foxp3
+ cells
b High (vs low) 0.85 (0.37–1.97) 0.70
Localisation pattern Diffuse (vs peri-tumour) 4.65 (1.35–15.96) 0.0147 1.98 (0.42–9.39) 0.39
Infiltration type
a INF-g (vs INF-a+INF-b) 5.56 (2.17–14.35) 0.0004 2.70 (0.67–10.94) 0.16
Histological classification Diffuse (vs intestinal) 3.13 (1.22–8.00) 0.0173 1.75 (0.33–9.17) 0.51
Lymphatic invasion Positive (vs negative) 23.13 (3.09–173.09) 0.0022 8.44 (0.53–133.92) 0.13
Vascular invasion Positive (vs negative) 9.43 (3.40–26.32) o0.0001 5.41 (1.10–26.32) 0.037
95% CI¼95% confidence interval; HR¼hazard ratio; INF¼infilteration.
aTumour, lymph node metastasis, stage, and infiltration type according to the Japanese Classification of
Gastric Carcinoma (Japanese Gastric Cancer Association, 1998).
bFoxp3
+-high and Foxp3
+-low groups were classified by the median value of the total population of Foxp3
+ cells
(median¼34.5, range¼2–525).
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